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Abstract
Significant improvements have been noted in heart transplantation
with the advent of cyclosporine. However, cyclosporine use is associ-
ated with significant side effects, such as chronic renal failure. We
were interested in evaluating the incidence of long-term renal dys-
function in heart transplant recipients. Fifty-three heart transplant
recipients were enrolled in the study. Forty-three patients completed
the entire evaluation and follow-up. Glomerular (serum creatinine,
creatinine clearance measured, and creatinine clearance calculated)
and tubular functions (urinary retinol-binding protein, uRBP) were re-
analyzed after 18 months. At the enrollment time, the prevalence of
renal failure ranged from 37.7 to 54% according to criteria used to
define it (serum creatinine ≥1.5 mg/dL and creatinine clearance <60
mL/min). Mean serum creatinine was 1.61 ± 1.31 mg/dL (range 0.7 to
9.8 mg/dL) and calculated and measured creatinine clearances were
67.7 ± 25.9 and 61.18 ± 25.04 mL min-1 (1.73 m2)-1, respectively.
Sixteen of the 43 patients who completed the follow-up (37.2%) had
tubular dysfunction detected by increased levels of uRBP (median
1.06, 0.412-6.396 mg/dL). Eleven of the 16 patients (68.7%) with
elevated uRBP had poorer renal function after 18 months of follow-
up, compared with only eight of the 27 patients (29.6%) with normal
uRBP (RR = 3.47, P = 0.0095). Interestingly, cyclosporine trough
levels were not different between patients with or without tubular and
glomerular dysfunction. Renal function impairment is common after
heart transplantation. Tubular dysfunction, assessed by uRBP, corre-
lates with a worsening of glomerular filtration and can be a useful tool
for early detection of renal dysfunction.
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Introduction
Heart transplantation is considered to be
the best therapeutic option for patients with
end-stage heart failure. In the cyclosporine
era, there was a significant improvement in
the survival rate of solid organ transplanta-
tion, including the heart (1). The main bar-
rier to graft success, acute rejection, was
overcome by the use of cyclosporine. One-
year graft survival is now considered to be
about 91% in patients after hospital discharge
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(2). However, cyclosporine usage has been
associated with several side effects, mainly
hypertension, hyperlipidemia, hyperurice-
mia, gingival hyperplasia, hypertrichosis,
neurotoxicity, glucose intolerance, and re-
nal toxicity (3-5).
Cyclosporine causes two forms of neph-
rotoxicity: functional or acute nephrotoxic-
ity and structural or chronic nephrotoxicity.
Functional nephrotoxicity is related to the
dose of cyclosporine, may be reversible with
drug withdrawal, is associated with alter-
ations in renal hemodynamics and glomeru-
lar filtration rate that begin soon after initia-
tion of cyclosporine treatment and is largely
mediated by an imbalance of vasoconstric-
tors and vasodilators. The renal vasculature
is primarily affected in cyclosporine-related
functional nephrotoxicity. Structural or chronic
nephrotoxicity may not be reversible and
often is progressive, involving both the renal
arterioles and tubules, and may be mecha-
nistically distinct from functional nephro-
toxicity (6).
Cyclosporine usage in heart transplant
patients has been linked to nephrotoxicity
that ranges from mild renal function impair-
ment to severe renal failure, needing substi-
tutive renal replacement therapy (7-9).
Several studies have evaluated the preva-
lence of chronic renal failure among heart
transplant patients. Its prevalence ranged
from 3 to 10%, probably due to differences
in the transplant follow-up time, to the crite-
ria used to define renal impairment, to the
cyclosporine dose used in the maintenance
phase of transplantation, and to the inter-
population variability (2,7,10-19). Recently,
it has been demonstrated in a large group of
patients that heart transplantation is associ-
ated with a 10.9% 5-year cumulative inci-
dence of chronic renal failure (20).
We have demonstrated that heart trans-
plant patients with tubular dysfunction had a
worsening of renal function, mainly due to
cyclosporine nephrotoxicity. Tubular dys-
function was evaluated by measurements of
urinary retinol-binding protein (uRBP), a
low-molecular weight protein that is totally
filtered by the glomeruli and is almost com-
pletely reabsorbed by proximal tubules, there-
fore making it a good marker of tubular
function (21,22).
There is an impending consensus that
renal failure is associated with higher mor-
tality in heart transplant patients, demon-
strating the impact of this event on patient
outcomes (7,20). Indeed, it was observed
that heart transplanted patients with renal
failure had a 1.5 times higher mortality rate
than chronic renal failure patients in the first
year of hemodialysis therapy (18,23). How-
ever, the criterium used to define end-stage
renal failure in heart transplant recipients is
variable, with some investigators using se-
rum creatinine values and others estimating
renal function by measuring serum and uri-
nary levels of creatinine in 24-h voided urine.
Tubular dysfunction is rarely assessed, al-
though considered to be a relevant factor
for renal function prognosis. In the present
study, we analyzed the incidence of glo-
merular and tubular dysfunctions in heart
transplant patients and correlated it with re-
nal outcomes.
Material and Methods
Subjects
The study was conducted at the Nephrol-
ogy and Cardiology Divisions of Universi-
dade Federal de São Paulo and was ap-
proved by the Ethics Committee for Human
Study of the institution. All patients read,
accepted and signed an informed consent
term before being enrolled. Among the 56
patients followed at our clinic, 53 agreed to
participate in this study and were enrolled.
Of the 53 patients, 43 (76.7%) participated
in the entire evaluation and follow-up from
December 1999 to December 2001 (18
months). The median post-transplantation
time was 66.9 months (range 6-167 months).
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The demographic data of the patients are
shown in Table 1.
Renal function evaluation
Serum creatinine levels (mg/dL), 24-h
creatinine clearance (measured) corrected
for total body surface (mL min-1 (1.73 m2)-1)
and Cockcroft Gault creatinine clearance
(estimated; glomerular evaluation) (24), 24-
h proteinuria and uRBP levels (tubular evalu-
ation) were determined at enrollment and at
the end of the follow-up (18 months). Serum
and urinary creatinines were measured using
semi-automatized Hitachi methodology (col-
orimetric assay based on the modified Jaffe
method). uRBP was determined by a mono-
clonal antibody immunoenzymometric as-
say and the upper normal limit was consid-
ered to be 0.400 mg/L and the lower sensi-
tivity was 0.001 mg/L according to Pereira
et al. (21,22,25) who observed that uRBP
concentrations in 95 normal adults ranged
from 0.004 to 0.385 mg/L, defining normal
uRBP <0.400. All assays were done at the
same time excluding interassay variation.
The intra-assay variation was <6.6%.
Urine samples were collected and frozen
until RBP determination. No conservative
or special precautions were considered to
be necessary since RBP is stable in urine.
Briefly, 96-well plates (Nunc A/S, Roskilde,
Denmark) were coated with 100 µL of a
solution containing monoclonal antibody,
10 mg/L, in coating buffer. After overnight
incubation at 4ºC, the wells were washed
three times and 100 µL of the samples was
added. After incubation for 2 h at 37ºC, the
wells were washed and the biotinylated anti-
body was added. After 1 h of incubation,
streptavidin-peroxidase and the color reagent
(Amersham Pharmacia Biotech, Little Chal-
font, Buckinghamshire, UK) were added in
sequence. Absorbance rates were read at
490 nm in a plate reader (Model EL 311;
Bio-Tek Instruments Inc., Winooski, VT,
USA). Concentrations in the samples were
calculated by comparison with the standard
curve, prepared by using nonlinear regres-
sion, usually as a third-degree polynomial.
Renal failure was defined when patients
had serum creatinine levels above 1.5 mg/dL
or creatinine clearance below 60 mL min-1
(1.73 m2)-1 (measured or estimated creati-
nine clearance). According to the K/DOQI
study (26) and, more recently, to the KDIGO
study (27), chronic kidney disease is defined
as kidney damage or a glomerular filtration
rate of <60 mL min-1 (1.73 m2)-1 for 3 months
or more, irrespective of cause. Worsening of
renal function was defined as a change of
20% or higher in the basal level of serum
creatinine during follow-up.
Patients with good glomerular function
(creatinine levels under 1.5 mg/dL) and al-
tered tubular function (uRBP >0.400 mg/L)
were presumed to be at a higher risk of
developing renal failure (21,22).
Renal dysfunction prevalence data were
analyzed in the 53 patients who agreed to
participate. Of these, 43 completed the en-
tire follow-up period for the analysis of the
worsening of tubular and renal function.
Table 1. Demographic and clinical characteristics of the patients studied (N = 53).
Age (years) 49.2 ± 12.5
Male sex 86.6%
Post-transplantation time (months) 66.9 ± 35.3
End-stage heart disease
Dilated 71.7%
Ischemic 22.6%
Others 5.7%
Systemic arterial hypertension 88.7%
High serum cholesterol levels 60.4%
Immunosuppressive drugs dose (mg kg-1 day-1)
Cyclosporine 3.2 ± 0.6
Azathioprine 1.6 ± 0.5
Prednisone 0.13 ± 0.06
Cyclosporine trough levels (ng/mL) 196 ± 90.6
Cholesterol levels (mg/dL)
Total 194.2 ± 52.3
HDL 43.2 ± 20.5
LDL 117.4 ± 38.8
Triglycerides levels (mg/dL) 151 ± 70.8
Uric acid (mg/dL) 7.3 ± 2.2
Proteinuria in isolated sample (g/L) 0.3 ± 0.5
Data are reported as means ± SD unless otherwise stated.
1308
Braz J Med Biol Res 39(10) 2006
R. Chinen et al.
Biochemical analyses were also per-
formed in our study population in Roche/
Hitachi 912, including determination of to-
tal cholesterol and fractions, triglycerides,
glycemia, and uric acid levels. Cholesterol
and HDL were determined by an enzymatic
colorimetric assay using cholesterol esterase
and cholesterol oxidase, triglycerides were
determined by the enzymatic colorimetric
assay Trinder endpoint reaction, and uric
acid was determined by an enzymatic color-
imetric assay using uricase and peroxidase.
Statistical analysis
Data are reported as means ± SD unless
otherwise stated. Parametric and non-para-
metric tests, the chi-square and exact Fisher
tests were used to compare the groups. The
differences were considered statistically sig-
nificant when P < 0.05. The statistical anal-
ysis was performed with the SPSS 10.0 for
Windows software.
Results
Demographic data
Of the 56 patients followed at our outpa-
tient clinic, 53 (94.6%) agreed to participate
in this study, being submitted to all clinical
and laboratory evaluations. However, only
43 (76.7%) completed entire 18-month evalu-
ation. The median post-transplantation time
was 66.9 months (range 6-167). Our en-
rolled population was predominantly male
(86.6%), Caucasian (75.5%) and 49.2 ± 12.5
years old. The etiologies of terminal heart
failure were mainly dilated (71.7%) and is-
chemic cardiomyopathies (22.6%). Chagas’
disease was present in 39.5% of the patients
with dilated cardiomyopathy. The demo-
graphic profile is detailed in Table 1.
Most of the patients (83%) were on
double-based immunosuppressive therapy,
cyclosporine/steroid or cyclosporine/azathio-
prine. All patients but one were treated with
cyclosporine-based immunosuppression (the
exception used Tacrolimus for two years
after a recurrent acute rejection). The mean
cyclosporine trough level was 196 ± 90.6
ng/mL (Table 1). The incidence of hyperten-
sion and dyslipidemia along with the daily
immunosuppressive drugs are also presented
in Table 1.
Renal dysfunction prevalence
Glomerular filtration rate was evaluated
by three methods: routine serum creatinine
measurements, creatinine clearance calcu-
lated after 24-h voided urine collection, and
by the Cockcroft-Gault formula. Consider-
ing the entire population, the mean serum
creatinine level was 1.30 mg/dL (0.6-3.8).
Calculated and measured creatinine clear-
ances were 67.7 ± 25.9 mL/min and 61.18 ±
25.04 mL min-1 (1.73 m2)-1, respectively.
The prevalence of renal failure varied, as did
the criteria used by us to define it. When
considering the serum creatinine levels (cut-
off of 1.5 mg/dL) commonly used in clinical
evaluations, we observed that 20 patients
(37.7%) had levels above 1.5 mg/dL. Con-
sidering a measured creatinine clearance
below 60 mL min-1 (1.73 m2)-1, the preva-
lence was higher (54%). Further refinement
using estimated creatinine clearance below
60 mL/min showed that this prevalence was
38%. Interestingly, after the beginning of
the present study, one patient needed renal
replacement therapy with dialysis (2.3%)
and another was successfully renal grafted
(2.3%).
When we divided the groups by the level
of estimated creatinine clearance, we ob-
served that they were similar concerning age
of recipient, time of transplantation, immu-
nosuppressive drug dosage, cyclosporine
trough levels, and 24-h proteinuria (data not
shown).
Considering all patients who completed
the entire follow-up (43 patients), their ini-
tial and final serum creatinine levels were
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1.405 ± 0.517 and 1.633 ± 0.539 mg/dL,
respectively.
Tubular dysfunction prevalence
We investigated the incidence of tubular
dysfunction by measuring a low-molecular
weight tubular protein, RBP, in urine. Only
patients who participated through the entire
follow-up were included (43 patients). Pre-
viously, we demonstrated that urinary levels
of RBP correlate with tubular dysfunction
and later with graft survival (20,21). uRBP
was higher in patients with creatinine clear-
ance below 60 mL min-1 (1.73 m2)-1 (0.608 ±
1.12 vs 0.173 ± 0.153 mg/L, P = 0.037).
Sixteen patients (37.2%) presented higher
levels of uRBP (1.06, 0.412-6.396 mg/L)
and 27 (62.8%) patients had normal levels
(0.128, 0.009-0.395 mg/L, P < 0.01). High
uRBP levels at the beginning of the study
were significantly correlated with the 18-
month serum creatinine levels (R = 0.562, P
< 0.001; Figure 1), but not with cyclosporine
trough levels (R = -0.01, P > 0.05). Indeed,
patients with high and normal uRBP had
similar cyclosporine trough levels (213.9 ±
180.2 and 177.8 ± 101.7 ng/mL, respective-
ly; P = 0.509; Table 2).
Eleven of the 16 patients (68.7%) with
tubular dysfunction had poorer renal func-
tion by the end of follow-up compared with
8 of 27 (29.6%) patients with normal uRBP.
Indeed, uRBP above 0.400 mg/L had a rela-
tive risk of 3.47 of poorer renal function
over one year (95% CI = 1.2919-9.3320, P =
0.0095). The initial and final serum creati-
nine levels of patients with adequate glo-
merular and tubular function were 1.053 ±
0.184 and 1.321 ± 0.278 mg/dL, respective-
ly. Considering patients with tubular dys-
function, their initial and final serum creati-
Figure 1. Pearson’s correlation
between urinary retinol-binding
protein (uRBP) levels and se-
rum creatinine after 18 months
(R = 0.562, P < 0.001).
Table 2. Comparative analysis of characteristics of the patients studied according to estimated creatinine
clearance (CrCl ) and urinary retinol-binding protein (uRBP).
Variables Estimated CrCl uRBP
<60 mL/min ≥60 mL/min ≤0.400 mg/L >0.401 mg/L
Age (years) 52.94 ± 10.09 46.58 ± 11.07 48.9 ± 11.1 49.5 ± 11.3
Transplantation time (months) 75.1 ± 34.4 61.38 ± 32.7 63.1 ± 36 75.2 ± 26.8
Immunosuppressive dose (mg kg-1 day-1)
Prednisone 0.089 ± 0.03 0.12 ± 0.05 0.08 ± 0.05 0.15 ± 0.04
Azathioprine 1.51 ± 0.52 1.73 ± 0.48 1.63 ± 0.49 1.86 ± 1.26
Cyclosporine 2.90 ± 0.6 3.2 ± 0.6 3.07 ± 0.58 3.09 ± 0.67
Cyclosporine trough levels (ng/mL) 204.2 ± 80.6 209.7 ± 90.9 177.8 ± 101.7 213.9 ± 180.2
Total cholesterol (mg/dL) 196.2 ± 47.8 194.9 ± 57.3 189.6 ± 38.6 197.9 ± 53.7
Triglyceride levels (mg/dL) 160.4 ± 53.1 135.2 ± 74.6 146 ± 70.3 161.7 ± 62.4
Serum creatinine (mg/dL) 1.7 ± 0.63 1.2 ± 0.30* 1.33 ± 0.45 1.85 ± 067*
Calculated CrCl (mL/min) 51.5 ± 23.2 65.5 ± 20.0 51.7 ± 22.8 39.1 ± 12.6
Estimated CrCl (mL/min) 51.17 ± 12.61 81.31 ± 20* 71.9 ± 21.1 50.1 ± 14*
24-h proteinuria (g/L) 0.55 ± 0.99 0.051 ± 0.11* 0.03 ± 0.09 0.775 ± 1.09*
uRBP (mg/L) 1.166 ± 1.665 0.283 ± 0.301* 0.166 ± 0.12 1.50 ± 1.63*
*P < 0.05 compared to group with lower CrCl or uRBP value (t-test).
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nine was 1.200 ± 0.245 and 1.450 ± 0.214
mg/dL, respectively.
Discussion
Cyclosporine was vital for the success of
heart transplantation, being responsible for
improving patient survival rate in the 1980-
90’s. However, cyclosporine, as a calcineu-
rin inhibitor, has important side effects,
namely acute and chronic toxicity. Acute
toxicity is commonly seen in kidney recipi-
ents in the first weeks post-transplantation
as an impairment in renal function associ-
ated with hypertension, proximal tubular
dysfunction and normal histology in a graft
biopsy. During its chronic usage, cyclo-
sporine is related to interstitial fibrosis and
tubular atrophy, a feature commonly de-
scribed as chronic nephrotoxicity. The clini-
cal importance of cyclosporine nephrotoxic-
ity in the heart transplantation setting is the
cumulative incidence of renal failure and its
impact on patient survival. Senechal et al.
(28) have shown that end-stage renal failure
was associated with an increased risk of
mortality in heart recipients and that hyper-
triglyceridemia correlates with cardiac mor-
tality (relative risk of 3.89).
Several studies demonstrated a high inci-
dence of end-stage renal failure. Rubel et al.
(29) demonstrated a 20% incidence of end-
stage renal failure in a group of 320 heart
transplant recipients. Through actuarial analy-
ses, they showed that glomerular filtration
rate decreased by 24% during the first year
and, after 10 years of follow-up, 20% of the
patients had developed end-stage renal fail-
ure. The cyclosporine trough levels in the
first 6 months and the presence of diabetes
correlated with renal failure. Hetzer et al.
(16) demonstrated that 58 of 77 (75.32%)
heart transplant patients with 11-13 years of
post-transplantation time had some degree
of renal dysfunction, with a mean serum
creatinine of 2.09 ± 1.5 mg/dL. Moreover, 7
patients (9.09%) were on dialysis treatment.
One issue that needs to be raised is that
the definition and the measurement of glo-
merular filtration rate in heart transplant pa-
tients have not been established. Here, we
report a 30-54% prevalence of renal dys-
function in heart transplant recipients, simi-
lar to that reported by others (2,7,10-20).
When we considered creatinine clearance
(<60 mL min-1 (1.73 m2)-1), we could ob-
serve that serum creatinine (>1.5 mg/dL)
underestimated the real incidence, indicat-
ing that its routine interpretation should be
made with caution. Although serum creati-
nine is currently used in the clinical manage-
ment of transplant patients, there is evidence
suggesting that it does not reflect glomerular
filtration rate. Many investigators are under-
taking clinical trials to validate other bio-
markers such as cystatin C as a better renal
function index (30). Others suggest that esti-
mated creatinine clearance using Cockcroft-
Gault’s formula could provide more infor-
mation since it correlates with calculated
creatinine clearance. Although most studies
imply a role for calcineurin inhibitors in the
pathogenesis of renal failure, a direct corre-
lation between them based on their trough
levels or on their daily concentration has not
been totally established. By univariate anal-
ysis, we could not implicate a role for cyclo-
sporine, cholesterol or triglyceride levels in
renal failure. Patients with renal dysfunction
estimated by the Cockcroft-Gault formula
had only uRBP levels different from those
with normal rates. It is possible that an asso-
ciation of direct renal effects through induc-
tion of renal hypoxia and an indirect action,
such as hypertension and dyslipidemia, could
actually determine renal dysfunction that
ultimately progresses to end-stage renal fail-
ure.
Chronic renal failure can increase the
mortality rate in heart transplant patients.
New protocols advocate calcineurin inhibi-
tor withdrawal or the addition of mycopheno-
late mofetil and rapamicyn to the treatment
of recipients with renal function impairment.
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Groetzner et al. (31,32) conducted a pro-
spective study in which heart transplant re-
cipients with impaired renal function, possi-
bly due to calcineurin inhibitor-related tox-
icity, were converted to mycophenolate mofe-
til and rapamicyn therapy. After the conver-
sion, renal function improved significantly
and, more importantly, with no serious side
effects.
Additionally, we also evaluated tubular
dysfunction in these heart transplant patients.
Although glomerular involvement is associ-
ated with renal failure, tubule-interstitial
dysfunction is in fact better correlated with
kidney outcomes. Usually, evaluation of tu-
bule-interstitial dysfunction is neglected in
transplant recipients; however, its impact on
graft survival in kidney transplant patients
has long been described. LeBidois et al. (33)
demonstrated that tubular and interstitial le-
sions were present in renal biopsies of pedi-
atric heart transplant patients on cyclo-
sporine-based immunosuppressive therapy.
The measurement of uRBP is a useful
noninvasive method for the diagnosis of tu-
bular dysfunction. RBP is a low-molecular
weight protein that is totally filtered and
almost completely reabsorbed by the proxi-
mal tubules. There is no known condition
associated with its high serum protein levels
and the protein is very stable in the entire
range of urinary pH (25). Our group has
demonstrated the importance of uRBP in
predicting renal graft failure in heart and
kidney transplanted recipients (21,22,34).
We have recently addressed the question
of whether tubular dysfunction has a nega-
tive impact on renal function and graft sur-
vival. Thirty-six heart transplant recipients
were studied and RBP was measured in urine.
Patients with higher levels of uRBP had
impaired renal function with a relative risk
of 3.87 (P = 0.003) to double serum creati-
nine level over a 5-year of follow-up. In
renal transplantation, uRBP levels were as-
sociated with chronic allograft nephropathy
and with decreased long-term graft survival
(34). Therefore, we were interested in inves-
tigating the prevalence of glomerular and
tubular dysfunction in a larger group of pa-
tients in correlation with their renal out-
comes.
Initially, we observed a prevalence of
37.2% (16/43 patients) of tubular dysfunc-
tion in the 43 patients who completed the
entire evaluation. Of note, 11/16 patients
(68.7%) with high uRBP levels presented a
deterioration of glomerular renal function
over the follow-up time compared to 8/27
(29.6%) of patients with normal uRBP lev-
els. High uRBP levels were then associated
with a relative risk of 3.47 of progressing
renal function (P = 0.0095). Although, the
cyclosporine trough levels were slightly
higher in patients with elevated uRBP lev-
els, they did not differ significantly for those
with or without tubular dysfunction. Total
exposure time and individual susceptibility
could be related to the side effects of cyclo-
sporine.
We showed that serum creatinine levels
significantly correlate with uRBP levels. In
the present study group, 8 patients presented
normal glomerular filtration, but altered tu-
bular function, indicating the beginning of
renal damage. This condition establishes a
gap between the diagnosis of tubular renal
damage and the decrease in glomerular fil-
tration rate. This gap can be defined as an
“opportunity gap” that could allow initiation
of a preventive therapy in an attempt to halt
progression of the lesion. Changes in immu-
nosuppressive drugs such as reducing the
cyclosporine dose can be this preventive
therapy.
A combination of cyclosporine-induced
hemodynamic changes and direct toxic ef-
fects of cyclosporine on tubular epithelial
cells may lead to the structural lesions char-
acteristic of chronic cyclosporine nephro-
toxicity. Cyclosporine may advance these
lesions by promoting two interrelated patho-
physiological processes. Sustained renal is-
chemia and enhanced apoptosis, and angio-
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tensin II may play important roles in both of
these processes. Proximal tubular cell injury
has been proposed to play a prominent role
in tubulointerstitial disease through the re-
lease of various substances affecting vaso-
constriction, the influx of inflammatory cells
into the interstitium, fibroblast proliferation,
and matrix synthesis. Injury to the proximal
tubular cells induced either by sustained is-
chemia secondary to enhanced cyclosporine-
related vasoconstriction or by direct toxic
effects of cyclosporine may cause the re-
lease of endothelin-1 and other substances.
This injury stimulates a local inflammatory
response which includes macrophage infil-
tration and osteopontin expression. Osteo-
pontin is a macrophage chemoattractant and/
or adhesion protein that facilitates the local-
ization of macrophages to the site of injury.
Both macrophages and tubular cells may
then release TGF-ß1, which promotes fibro-
sis by both increasing the expression and
decreasing the degradation of extracellular
matrix protein. Cyclosporine has also been
shown to activate apoptosis genes and to
increase apoptosis in tubular and interstitial
cells. Cyclosporine-induced apoptosis cor-
relates with tubular atrophy and tubulointer-
stitial fibrosis (6). Since renal impairment
due to cyclosporine nephrotoxicity is a com-
mon feature in heart transplant recipients,
patients were not subjected to a kidney bi-
opsy because their clinical and laboratory
data were compatible for this diagnosis.
Considering all of these correlations be-
tween cyclosporine and renal tubular lesion,
by lowering the cyclosporine dose we can
expect diminished toxicity to tubular cells
and consequently a decrease in uRBP levels.
Some investigators advocate genetic sus-
ceptibility to the nephrotoxic effect of cyclo-
sporine. Two recent studies (35,36) on heart-
transplanted patients suggest that the poly-
morphism of a TGF-ß1 gene can be involved
in the susceptibility to the nephrotoxic ef-
fects of cyclosporine. TGF-ß1 is a pro-fi-
brotic cytokine. It was demonstrated by sev-
eral investigators (37-39) that cyclosporine
promotes hyperexpression of this cytokine
both in vitro and in vivo.
In a 7-year follow-up of heart transplant
recipients, Baan et al. (36) demonstrated that
23 of a total of 89 patients (26%) who were
Leu/Pro heterozygotes or Pro/Pro homozy-
gotes presented renal insufficiency in con-
trast to only 3 of a total of 42 patients (7%)
who were Leu/Leu homozygotes. It is still in
discussion in the literature which genotype
in the codon 10 of TGF-ß1 is related to the
largest susceptibility to cyclosporine neph-
rotoxicity.
We presented data demonstrating a high
prevalence of renal dysfunction among heart
transplant recipients. We assessed tubular
dysfunction and demonstrated that it corre-
lates with a worsening of renal function over
time. Many times tubular dysfunction is de-
tected while glomerular filtration is adequate.
This may provide an opportunity to inter-
vene with changes in the immunosuppres-
sive drugs used in an attempt to avoid pro-
gression of the renal damage.
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